Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 3
2003 2
2004 2
2005 3
2006 4
2007 1
2008 1
2009 1
2010 3
2011 6
2012 5
2013 2
2014 5
2015 4
2016 7
2017 7
2018 9
2019 11
2020 16
2021 18
2022 10
2023 9
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

103 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of discovery rates and prognostic utility of [68Ga]Ga-PSMA-11 PET/CT and circulating tumor DNA in prostate cancer-a cross-sectional study.
Kluge K, Einspieler H, Haberl D, Spielvogel C, Amereller D, Egger G, Kramer G, Grubmüller B, Shariat S, Hacker M, Kenner L, Haug A. Kluge K, et al. Among authors: kramer g. Eur J Nucl Med Mol Imaging. 2024 May 2. doi: 10.1007/s00259-024-06698-7. Online ahead of print. Eur J Nucl Med Mol Imaging. 2024. PMID: 38693454
Real-World Evidence of Triplet Therapy in Metastatic Hormone-Sensitive Prostate Cancer: An Austrian Multicenter Study.
Kafka M, Giannini G, Artamonova N, Neuwirt H, Ofner H, Kramer G, Bauernhofer T, Luger F, Höfner T, Loidl W, Griessner H, Lusuardi L, Bergmaier A, Berger A, Winder T, Weiss S, Bauinger S, Krause S, Drerup M, Heinrich E, Schneider M, Madersbacher S, Vallet S, Stoiber F, Laimer S, Hruby S, Schachtner G, Nagele U, Lenart S, Ponholzer A, Pfuner J, Wiesinger C, Kamhuber C, Müldür E, Bektic J, Horninger W, Heidegger I. Kafka M, et al. Among authors: kramer g. Clin Genitourin Cancer. 2024 Apr;22(2):458-466.e1. doi: 10.1016/j.clgc.2023.12.018. Epub 2024 Jan 4. Clin Genitourin Cancer. 2024. PMID: 38267304 Free article.
Examining the Relationship and Prognostic Significance of Cell-Free DNA Levels and the PSMA-Positive Tumor Volume in Men with Prostate Cancer: A Retrospective-Prospective [68Ga]Ga-PSMA-11 PET/CT Study.
Kluge K, Einspieler H, Haberl D, Spielvogel C, Stoiber S, Vraka C, Papp L, Wunsch S, Egger G, Kramer G, Grubmüller B, Shariat S, Hacker M, Kenner L, Haug A. Kluge K, et al. Among authors: kramer g. J Nucl Med. 2024 Jan 2;65(1):63-70. doi: 10.2967/jnumed.123.266158. J Nucl Med. 2024. PMID: 38050125 Free PMC article.
Comparative proteome and serum analysis identified FSCN1 as a marker of abiraterone resistance in castration-resistant prostate cancer.
Csizmarik A, Nagy N, Keresztes D, Váradi M, Bracht T, Sitek B, Witzke K, Puhr M, Tornyi I, Lázár J, Takács L, Kramer G, Sevcenco S, Maj-Hes A, Hadaschik B, Nyirády P, Szarvas T. Csizmarik A, et al. Among authors: kramer g. Prostate Cancer Prostatic Dis. 2023 Aug 26. doi: 10.1038/s41391-023-00713-y. Online ahead of print. Prostate Cancer Prostatic Dis. 2023. PMID: 37634036
Performance of clinical risk scores and prediction models to identify pathogenic germline variants in patients with advanced prostate cancer.
Rebhan K, Stelzer PD, Pradere B, Rajwa P, Kramer G, Hofmann B, Resch I, Yurdakul O, Laccone FA, Bujalkova MG, Smogavec M, Tan YY, Ristl R, Shariat SF, Egger G, Hassler MR. Rebhan K, et al. Among authors: kramer g. World J Urol. 2023 Aug;41(8):2091-2097. doi: 10.1007/s00345-023-04535-4. Epub 2023 Aug 1. World J Urol. 2023. PMID: 37528288 Free PMC article.
Efficacy of Systemic Treatment in Prostate Cancer Patients With Visceral Metastasis: A Systematic Review, Meta-analysis, and Network Meta-analysis.
Yanagisawa T, Rajwa P, Kawada T, Mori K, Fukuokaya W, Petrov P, Quhal F, Laukhtina E, von Deimling M, Bianchi A, Majdoub M, Pradere B, Kramer G, Kimura T, Shariat SF. Yanagisawa T, et al. Among authors: kramer g. J Urol. 2023 Sep;210(3):416-429. doi: 10.1097/JU.0000000000003594. Epub 2023 Jun 20. J Urol. 2023. PMID: 37339479 Review.
Pembrolizumab Plus Olaparib for Patients With Previously Treated and Biomarker-Unselected Metastatic Castration-Resistant Prostate Cancer: The Randomized, Open-Label, Phase III KEYLYNK-010 Trial.
Antonarakis ES, Park SH, Goh JC, Shin SJ, Lee JL, Mehra N, McDermott R, Sala-Gonzalez N, Fong PC, Greil R, Retz M, Sade JP, Yanez P, Huang YH, Begbie SD, Gafanov RA, De Santis M, Rosenbaum E, Kolinsky MP, Rey F, Chiu KY, Roubaud G, Kramer G, Sumitomo M, Massari F, Suzuki H, Qiu P, Zhang J, Kim J, Poehlein CH, Yu EY. Antonarakis ES, et al. Among authors: kramer g. J Clin Oncol. 2023 Aug 1;41(22):3839-3850. doi: 10.1200/JCO.23.00233. Epub 2023 Jun 8. J Clin Oncol. 2023. PMID: 37290035 Free PMC article. Clinical Trial.
103 results